MTR 104

Drug Profile

MTR 104

Alternative Names: Difetur; MTR 104; MTR 105; MTR 106; MTR 107; Nitric oxide synthase inhibitors - Meditor

Latest Information Update: 28 May 2015

Price : $50

At a glance

  • Originator Meditor Pharmaceuticals
  • Class Antihypotensives; Antimigraines; Urea compounds
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypotension
  • Discontinued Migraine

Most Recent Events

  • 11 Jun 2008 Final efficacy data from a phase II trial in Migraine released by Meditor
  • 09 Nov 2007 Results from a phase II clinical trial in patients with Migraine added to the adverse events and Advances in the Treatment of Nausea and Migraine therapeutic trials sections
  • 04 Oct 2006 MTR 107 is available for licensing and development partners (http://www.meditorpharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top